RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
RAMOT at Tel Aviv University Ltd. posted this:Surface Plasmon Amplification of stimulated emissionSurface Plasmon Amplification of stimulated emission Project ID : 11-2011-127
RAMOT at Tel Aviv University Ltd. posted this:Low energy laser bio-stimulation of bone marrow stem cells for the treatment of myocardial infarctionHeart diseases are the leading cause of death worldwide. Low energy laser (light) irradiation has been shown to have bio-stimulatory beneficial effects on various biological processes in vitro, in vivo and also in clinical trails. We have explored the beneficial effects of light therapy (LT) on stem cells in the bone marrow in order to determine its potential application as cell therapy for the heart post myocardial infarction (MI). Preliminary results have shown that in the infarcted rat heart model the application of LT to the rat bone marrow (BM) in the hind leg 10 min and 4 hrs post MI caused a significant reduction of 79% and 75 % respectively in the scar tissue formed after MI. This is a novel, simple and non-invasive approach to improving heart function after heart attack in patients, and may also serve as a basis for cell therapy of other diseased organs. The fact that LT demonstrated efficacy in scar reduction 4 hours post MI, indicates its clinical relevance to treat patients post MI. Project ID : 2-2011-143
Research & Technology Organization
Universidad de Alicante posted this:Novel self-expanding polyurethane foams intended for inert filling of pleural and other human cavities.The Adhesion and Adhesives Laboratory of the University of Alicante has developed a new polymeric foaming material for in-situ filling and sealing of internal irregular different shaped human cavities, intended for patients suffering chronic pleural cavities and in-field injuries caused by bullets or accidental event leaving open blood vessels. The new foam is composed of two separate liquid components that can be mixed in a two-body syringe in such a way that the foaming time can be modulated for allowing the foam formation at the end of the syringe needle. The new polymeric foam can self-expanded and self-modelated for avoiding complications in open internal cavities caused by infections, blooding, fistulae, dyspnea or sepsis. The new foam is easily applicable, safe for biological tissues, and its use avoid the use of the current aggressive treatments in pleural cavities. It is looking for companies interested in acquiring this technology for its commercial exploitation.
Universidad de Alcalá-OTRI posted this:Walker for the mobility of people with motor disability.A research group from the Signal Theory and Communications Department of Alcalá University has developed a disability walker for improving the mobility of people with motor disability. This walker includes a guide for the leg together with an electronic system, that improves the user of manoeuvrability allowing the configuration of basic actions. This invention is part of the "Loyalty Technological Program," which has been designed by the research group to raise funds for the development and adaptation of technical aids that improve the quality of people life with motor impairments. The group is looking for collaboration agreements with institutions or companies that want to be part of the "Loyalty Technological Program" http://padrinotecnologico.org/proyectos/instituciones/ Moreover, the group is interested in reaching license, collaboration, manufacturing or commercial agreements with technical assistance with orthopaedics, medical equipment, and health technology companies. Other kind of institutions interested in sponsoring this invention are also welcome.
Fundació URV posted this:Potentiometric sensor for the quantitative determination of creatininePotentiometric sensor for the quantitative determination of creatinine in biological fluids and other aqueous media. By a new ionophore incorporated into a polymeric membrane that allows screening creatinine real samples. The use of said ionophore in the polymer membrane solve the selectivity problem found in other methods.
IMIM Institut Recerca Hospital del Mar posted this:New method for the determination of the risk of atypical fractures in patients treated with bone remodelling inhibitors.Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis
DIT Hothouse posted this:Optimisation of Posterior Spinal Dynamic (PSD) Stabilisation SurgeryOptimising spinal surgery techniques through the use of a hip and spine simulator and a tension and torsion test machine to treat spinal patient such as those with crushed vertebra and spinal deformities, like scoliosis.
DIT Hothouse posted this:U-Learn: A Training Model for Breast Ultrasound imagingU-learn is a training and learning model for radiographers and registrars for training in breast ultrasound imaging. The model assesses the performance of a trainee registrar before, during, and after training using the ultrasound imaging phantom which is a realistic representation of the breast.
Universidad de Alcalá-OTRI posted this:Device and method for ventricular repolarization alternans detection by windowing.A Spanish research group from the Department of Signal Theory and Communications at University of Alcalá (Spain) has designed a device and method for detecting ventricular repolarization alternans based on continuous time analysis and the extraction of the information using windowing. As a main feature, the method presents high robustness against noise and it is very robust against variability of heart rate due to standardization techniques used. Moreover, it includes a procedure to separate the repolarization information from artifacts. Because of these characteristics, it is particularly suitable for implementation in portable monitoring devices and implantable devices. The group is looking for companies of Medical equipment and health technology to reach licensing agreements or collaboration and commercial agreements for technical assistance.
Universidad de Alcalá-OTRI posted this:Double mesh prosthesis that corrects defects in the abdominal wall and prevents adhesion formation at the peritoneal interfaceA research group from the Surgery Department of Alcala University has designed an implantable prosthesis made of two meshes joined together, for abdominal surgery uses. This prosthesis prevents the erosion of the viscera by promoting mesothelial deposition. Both meshes induce fibroblast proliferation and collagen deposition achieving the definitive repair of the defect at the expense of connective tissue. This research group is looking for manufacturing and license agreements.
Fundació URV posted this:α-ketoglutarate as a predictor of morbid obesity-associated nonalcoholic fatty liver disease• Use of α-ketoglutarate as a novel biomarker of nonalcoholic fatty liver disease (NAFLD). • α-ketoglutarate analysis is a non-invasive quantitative measure of liver steatosis. • This method may reduce the need for liver biopsy, particularly in patients with metabolic risk factor. • The method could be used to design a kit to detect and quantify plasma α-ketoglutarate concentration. • Measurement of this biomarker may be useful in the assessment of NAFLD progression.